ReviewCurrent HIV/AIDS reports2025
Growing Up with HIV: A Comprehensive Review of Treatment and Care in Low- and Middle-Income Countries.
Review in Current HIV/AIDS reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewDespite declining numbers of new pediatric HIV infections and advancements in treatment for children and adolescents living with HIV (CALHIV), barriers remain. Comprehensive care for CALHIV in low- and middle-income countries is challenged by limited treatment options, unique psychosocial challenges, and caregiver reliance. Successful care relies on understanding the unique developmental needs, as well as their vulnerabilities to treatment failure and HIV drug resistance. RECENT
findingsCALHIV lag behind adults in meeting global UNAIDS targets. Increasing availability of pediatric fixed dose combinations (FDC) of abacavir/lamivudine/dolutegravir (ABC/3TC/DTG) may address some challenges but providing alternatives should be prioritized. Emerging evidence has demonstrated pre-treatment and acquired HIV drug resistance (HIVDR) are more prevalent in CALHIV. While novel therapies are in development, access remains a concern. Increased child and adolescent-friendly treatment options are needed to provide quality life-long comprehensive care to CALHIV in low- and middle-income countries (LMIC). Expanded research and access to novel therapies is key to close treatment gaps between CALHIV and their adult counterparts and address emerging HIV drug resistance.
Indexed as
Identifiers
41201656What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.